Finland· FI-REL-REL10445
Arava
A leflunomide product, registered in Finland by Sanofi-Aventis Deutschland GmbH. The same ATC class is registered in 15 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Leflunomide is registered in 15 of 19 countries.
Countries holding a registration under ATC L04AK01 (leflunomide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Leflunomide · ATC L04AK01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of leflunomide costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.47 in United States to $2.13 in Italy — a ×4.5 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Leflunomide · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- IT Italy$2.13
- CH Switzerland$1.48
- US United States$0.47 (acquisition cost)
The record
At a glance
Fimea (Finland)- Manufacturer
- Sanofi-Aventis Deutschland GmbH
- Country
- Finland (FI)
- ATC code
- L04AK01
- ATC class
- Leflunomide
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
805 interactions on record for leflunomide.
Graded by severity as the source publishes them — 537 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Leflunomide · interactions on record
805 records
- 537 severe
- 47 moderate
- 7 minor
- 214 info
Most severe, free to view
- ClotrimazoleA01AB18severe
- Chenodeoxycholic acidA05AA01severe
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AK01
Leflunomide, as other registers publish it.
- CanadaACCEL-LEFLUNOMIDEACCEL PHARMA INC
- CanadaACCEL-LEFLUNOMIDEACCEL PHARMA INC
- CanadaAPO-LEFLUNOMIDEAPOTEX INC
- CanadaAPO-LEFLUNOMIDEAPOTEX INC
- DenmarkAravaAventis Pharma Deutschland GmbH
- FinlandAravaSanofi-Aventis Deutschland GmbH
- United StatesAravasanofi-aventis U.S. LLC
- FinlandAravaSanofi-Aventis Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/649c8095-bd04-4f70-b395-319773bf7e9a GET /v1/drugs/649c8095-bd04-4f70-b395-319773bf7e9a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "20",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "100 mg",
"atc_label": "leflunomidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/99/118/009",
"fimea_rel_id": "REL10445",
"authorised_at": "1999-09-02"
}See everything about leflunomide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.